IHS Chemical Week

Regions :: Western Europe :: U.K.

Oxford BioTherapeutics Licenses Lonza’s GS Gene Expression System

12:04 AM MDT | September 2, 2011 | Deepti Ramesh

Lonza says it has signed a non-exclusive license agreement with biotechnology company Oxford BioTherapeutics (OBT; Abingdon, U.K.) that will provide OBT with access to Lonza’s GS Gene Expression System. The agreement covers the research, development and commercial use of the GS system by OBT. Financial details of the deal were not disclosed.  The GS Gene Expression System is used for the production of therapeutic recombinant proteins and monoclonal antibodies. Licensing of the GS Gene Expression System expands OBT’s access to technologies for its...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa